Clinical Trials Directory

Trials / Completed

CompletedNCT02116413

Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?

Status
Completed
Phase
Study type
Observational
Enrollment
145 (actual)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to evaluate in a population of patients with septic shock receiving 500 ml crystalloid over 10 minutes, the proportion of patients classified as "responders" to the fluid challenge (increase of at least 15% of ITV in aortic) at the end of vascular filling (T10) and becoming "non-responders" 20 minutes after the end of the fluid challenge (T30) and whether this proportion is greater than 10 points.

Detailed description

The secondary objectives of this study are : A. To assess changes in different ultrasound parameters: E wave , E / A ratio , E / E ' in the event of vascular filling and construct a dose response curve for vascular filling. B. To determing a threshold value for the mitral E wave velcoity that can predict a positive response to volume expansion at T10 defined by a 15% increase in the sub aortic velocity time integral (ITV) after 500 ml of crystalloids in 10 minutes. C. To determine a threshold value for theITV at T0 that can predict a positive response to volume expansion at T10 defined by a 15% increase in the ITV after 500 ml of crystalloids in 10 minutes. D. To evaluate the proportion of responders at T10 becoming non-responders at T20. E. To evaluate the proportion of nonresponders at T10 and responders at T30 . F. To estimate the proportion of patients changing status regardless of the direction of change between T10 and T30 .

Conditions

Interventions

TypeNameDescription
PROCEDUREFluid challengeThe fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
PROCEDURECardiac ultrasoundUltrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.

Timeline

Start date
2014-05-01
Primary completion
2016-01-08
Completion
2016-01-08
First posted
2014-04-16
Last updated
2025-11-19

Locations

9 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02116413. Inclusion in this directory is not an endorsement.